A new antibody has been developed to block immune suppression in aggressive breast cancer, offering a promising treatment.

After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...

Science Connected Magazine is an editorially independent, non-profit newsroom producing open-access science journalism and ...

INR:3433. coexchange login password Top tumor immunology companies at home and abroad have entered the TIGIT monoclonal antibody market and ushered in t ...

Whether the next pandemic is caused by H5N1 bird flu or something else, we must prepare now to use convalescent plasma to ...

INR:1237. phoenix rises lawn mowing simulator Top tumor immunology companies at home and abroad have entered the TIGIT monoclonal antibody mar ...

How is Indian Rummy played Top tumor immunology companies at home and abroad have entered the TIGIT monoclonal antibody market and ushered in ...

Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs for Dermatomyositis have a 60% phase transition success ...

UT Southwestern Medical Center researchers have identified a genetic mutation that slows the growth of melanoma and ...

Millions of individuals are affected by cancer each year. In response, different organizations and the federal government heavily invest in research to dev | Immunology ...

Daily science news on research developments and the latest scientific innovations Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech ...